Hu C - Search Results

1

Erratum to: Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis.

Hu C, Zhou H. Hu C, et al. J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):55. doi: 10.1007/s10928-015-9458-5. J Pharmacokinet Pharmacodyn. 2016. PMID: 26597150 No abstract available.

2

An improved approach for confirmatory phase III population pharmacokinetic analysis.

Hu C, Zhou H. Hu C, et al. J Clin Pharmacol. 2008 Jul;48(7):812-22. doi: 10.1177/0091270008318670. Epub 2008 May 19. J Clin Pharmacol. 2008. PMID: 18490499

3

Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.

Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H. Zhu Y, et al. Among authors: hu c. J Clin Pharmacol. 2009 Feb;49(2):162-75. doi: 10.1177/0091270008329556. J Clin Pharmacol. 2009. PMID: 19179295

4

Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.

Xu Z, Vu T, Lee H, Hu C, Ling J, Yan H, Baker D, Beutler A, Pendley C, Wagner C, Davis HM, Zhou H. Xu Z, et al. Among authors: hu c. J Clin Pharmacol. 2009 Sep;49(9):1056-70. doi: 10.1177/0091270009339192. Epub 2009 Jul 17. J Clin Pharmacol. 2009. PMID: 19617465 Clinical Trial.

5

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.

Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H. Fasanmade AA, et al. Among authors: hu c. Eur J Clin Pharmacol. 2009 Dec;65(12):1211-28. doi: 10.1007/s00228-009-0718-4. Epub 2009 Sep 16. Eur J Clin Pharmacol. 2009. PMID: 19756557 Free PMC article. Clinical Trial.

6

Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis.

Zhou H, Hu C, Zhu Y, Lu M, Liao S, Yeilding N, Davis HM. Zhou H, et al. Among authors: hu c. J Clin Pharmacol. 2010 Mar;50(3):257-67. doi: 10.1177/0091270009343695. Epub 2009 Nov 23. J Clin Pharmacol. 2010. PMID: 19934030 Clinical Trial.

7

Confirmatory analysis for phase III population pharmacokinetics.

Hu C, Zhang J, Zhou H. Hu C, et al. Pharm Stat. 2011 Jan-Feb;10(1):14-26. doi: 10.1002/pst.403. Pharm Stat. 2011. PMID: 20041468

8

Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis.

Hu C, Xu Z, Zhang Y, Rahman MU, Davis HM, Zhou H. Hu C, et al. J Clin Pharmacol. 2011 May;51(5):639-48. doi: 10.1177/0091270010372520. Epub 2010 Jul 9. J Clin Pharmacol. 2011. PMID: 20622199 Clinical Trial.

9

A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate.

Hu C, Xu Z, Rahman MU, Davis HM, Zhou H. Hu C, et al. J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):309-21. doi: 10.1007/s10928-010-9162-4. Epub 2010 Jul 16. J Pharmacokinet Pharmacodyn. 2010. PMID: 20635122 Clinical Trial.

10

Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.

Xu ZH, Lee H, Vu T, Hu C, Yan H, Baker D, Hsu B, Pendley C, Wagner C, Davis HM, Zhou H. Xu ZH, et al. Among authors: hu c. Int J Clin Pharmacol Ther. 2010 Sep;48(9):596-607. doi: 10.5414/cpp48596. Int J Clin Pharmacol Ther. 2010. PMID: 20860913 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,478 results

Search Page

Filters